<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843319</url>
  </required_header>
  <id_info>
    <org_study_id>V2010001</org_study_id>
    <nct_id>NCT04843319</nct_id>
  </id_info>
  <brief_title>To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer</brief_title>
  <acronym>VERU-100</acronym>
  <official_title>Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veru Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veru Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by&#xD;
      assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, open-label, dose finding study of VERU-100 to attain&#xD;
      and maintain serum total testosterone levels within castrate range (&lt;50ng/dL) in men with&#xD;
      advanced prostate cancer. Stage 1 of the study will assess the effect of VERU-100 at various&#xD;
      doses. Stage 2 will further assess the efficacy of the effective doses of VERU-100 in an&#xD;
      expanded patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2021</start_date>
  <completion_date type="Anticipated">February 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of men with total testosterone at &lt;50 ng/dL by day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Percent of men that reach castrate level (&lt;50 ng/dL) of total testosterone levels by Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total testosterone below 20ng/dL levels on VERU-100</measure>
    <time_frame>Day 28 and Day 91</time_frame>
    <description>Percent of men that reach &lt;20 ng/dL of total testosterone levels by Day 28 that are maintained at &lt;20 ng/dL through Day 91</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Advanced Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>VERU-100 at various doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg, 200mg or 300mg of VERU-100</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VERU-100</intervention_name>
    <description>GnRH antagonist</description>
    <arm_group_label>VERU-100 at various doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be over 18 years of age&#xD;
&#xD;
          -  Be able to communicate effectively with the study personnel&#xD;
&#xD;
          -  Have histologically confirmed prostate cancer&#xD;
&#xD;
          -  Have prostate cancer staged T3-4NxMx or TxN1Mx or TxNxM1 according to the TNM&#xD;
             classification or the patient should have rising PSA after failed local therapy and be&#xD;
             candidate for androgen deprivation therapy&#xD;
&#xD;
          -  Have a QTc interval &lt;440 ms&#xD;
&#xD;
          -  Subjects are judged by the attending physician and/or Principal Investigator to be a&#xD;
             candidate for androgen deprivation therapy (continuous therapy)&#xD;
&#xD;
          -  ECOG performance status of 0 to 2&#xD;
&#xD;
          -  Baseline morning serum testosterone levels &gt;150 ng/dL at Screening Visit&#xD;
&#xD;
          -  Have a life expectancy of ≥18 months&#xD;
&#xD;
          -  Subjects must agree to use acceptable methods of contraception&#xD;
&#xD;
               1. If their female partners are pregnant or lactating, acceptable methods of&#xD;
                  contraception from the time of the first administration of study medication until&#xD;
                  6months following administration of the last dose of study medication must be&#xD;
                  used. Acceptable methods are: Condom used with spermicidal&#xD;
                  foam/gel/film/cream/suppository. If the subject has undergone surgical&#xD;
                  sterilization (vasectomy with documentation of azoospermia),a condom with&#xD;
                  spermicidal foam/gel/film/cream/suppository should be used.&#xD;
&#xD;
               2. If the male subject's partner could become pregnant, use acceptable methods of&#xD;
                  contraception from the time of the first administration of study medication until&#xD;
                  6 months following administration of the last dose of study medication.&#xD;
                  Acceptable methods of contraception are as follows: Condom with spermicidal&#xD;
                  foam/gel/cream/suppository [i.e.,barrier method of contraception], surgical&#xD;
                  sterilization (vasectomy with documentation of azoospermia) and a barrier method&#xD;
                  {condom used with spermicidal foam/gel/film/cream/suppository}, the female&#xD;
                  partner uses oral contraceptives (combination estrogen/progesterone pills),&#xD;
                  injectable progesterone or subdermal implants and a barrier method (condom used&#xD;
                  with spermicidal foam/gel/film/cream/suppository).&#xD;
&#xD;
               3. If the female partner has undergone documented tubal ligation (female&#xD;
                  sterilization), a barrier method (condom used with spermicidal&#xD;
                  foam/gel/film/cream/suppository) should also be used.&#xD;
&#xD;
               4. If the female partner has undergone documented placement of an intrauterine&#xD;
                  device (IUD) or intrauterine system (IUS),a barrier method (condom with&#xD;
                  spermicidal foam/gel/film/cream/suppository) should also be used.&#xD;
&#xD;
          -  Laboratory values within the following ranges: hemoglobin ≥10 gm/dL, total bilirubin&#xD;
&#xD;
               -  1.5x upper limit of normal (ULN), AST ≤2.5x ULN, ALT ≤2.5x ULN,&#xD;
&#xD;
               -  1.5 mg/dL, absolute neutrophil count ≥1500 cell/uL and platelets ≥100,000&#xD;
                  cells/uL.&#xD;
&#xD;
          -  Creatinine clearance ≥60 mL/min based on Cockcroft-Gault equation.&#xD;
&#xD;
          -  Subject is willing to comply with the requirements of the protocol through the end of&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior androgen deprivation therapy within 6 months prior to Screening Visit.&#xD;
&#xD;
          -  Potentially curable disease receiving ADT for localized disease&#xD;
&#xD;
          -  History of bilateral orchiectomy, adrenalectomy, or hypophysectomy&#xD;
&#xD;
          -  Received chemotherapy, cryotherapy, or antiandrogen therapy within 8 weeks prior to&#xD;
             the Screening visit for the treatment of prostate cancer.&#xD;
&#xD;
          -  Known hypersensitivity to cetrorelix or other LHRH antagonists&#xD;
&#xD;
          -  History of Torsade de Pointes&#xD;
&#xD;
          -  Currently taking QT-prolonging drugs&#xD;
&#xD;
          -  Any disease or condition (medical or surgical) which might compromise the hematologic,&#xD;
             cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central&#xD;
             nervous system; or other conditions that may interfere with the absorption,&#xD;
             distribution, metabolism or excretion of study drug, or would place the subject at&#xD;
             increased risk&#xD;
&#xD;
          -  Use of exogenous testosterone within 6 months of Screening Visit&#xD;
&#xD;
          -  Use of 5α-reductase inhibitor within 3 months of Screening Visit&#xD;
&#xD;
          -  Use of systemic corticosteroids at a dose &gt;10 mg/day at Screening&#xD;
&#xD;
          -  Major surgery within 4 weeks of Screening Visit (including surgery for prostate&#xD;
             cancer)&#xD;
&#xD;
          -  Uncontrolled symptomatic congestive heart failure (NYHA Class III -IV), unstable&#xD;
             angina pectoris, cardiac arrhythmia, or uncontrolled atrial fibrillation&#xD;
&#xD;
          -  History of diabetes mellitus Type 1. Uncontrolled diabetes mellitus Type 2 (control&#xD;
             with oral hypoglycemic agents are allowed)&#xD;
&#xD;
          -  Received an investigational drug within a period of 90days prior to enrollment in the&#xD;
             study&#xD;
&#xD;
          -  Received the study medication (VERU-100) previously&#xD;
&#xD;
          -  Have been previously diagnosed or treated for active cancer(other than prostate cancer&#xD;
             or non-melanoma skin cancer) within the previous five years&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernette</last_name>
    <role>Study Chair</role>
    <affiliation>Veru Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barnette, MD</last_name>
    <phone>800-606-9382</phone>
    <email>veruclinicaltrials@verupharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodriguez</last_name>
    <phone>18006069382</phone>
    <email>veruclinicaltrials@verupharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Urology Specialists, PLLC</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gladis Solis</last_name>
      <phone>602-734-0309</phone>
      <email>gsolis@arizonauro.com</email>
    </contact>
    <investigator>
      <last_name>Roscoe Nelson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Institute of Urology, PLLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Placencia</last_name>
      <phone>520-784-7019</phone>
      <email>cplacencia@aiurology.com</email>
    </contact>
    <investigator>
      <last_name>Kalpesh Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Associates of Southern Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina S Montijo</last_name>
      <phone>520-351-5582</phone>
      <email>christinam@uasapc.com</email>
    </contact>
    <investigator>
      <last_name>Susan Kalota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Urology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie O'Brien</last_name>
      <phone>501-219-8900</phone>
      <email>katie@arkansasurology.com</email>
    </contact>
    <investigator>
      <last_name>Jeff Marotte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Bernardino Urological Associates</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxie Miller</last_name>
      <phone>909-882-2973</phone>
      <email>rmillersbua@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Franklin Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foothills Urology, PC</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Aggers</last_name>
      <phone>303-996-9649</phone>
      <email>deb@foothillsurologypc.com</email>
    </contact>
    <investigator>
      <last_name>David Cahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Urology, PSC</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Nessel</last_name>
      <phone>812-206-8161</phone>
      <email>cnessel@1sturology.com</email>
    </contact>
    <contact_backup>
      <last_name>Debbie Johnson</last_name>
      <email>djohnson@1sturology.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Bailen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Thomas</last_name>
      <phone>443-738-8188</phone>
      <email>hthomas@chesuro.com</email>
    </contact>
    <contact_backup>
      <last_name>Claire R Biesecker</last_name>
      <phone>443-471-5740</phone>
      <email>cbiesecker@chesuro.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald Tutrone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of NY, PLCC</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah N Faisal</last_name>
      <phone>315-478-4185</phone>
      <email>sfaisal@ampofny.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Pieczonka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Urologists of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kip N Moffett</last_name>
      <phone>919-390-7368</phone>
      <email>kmoffett@auncurology.com</email>
    </contact>
    <investigator>
      <last_name>Mark Jalkut</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Kalapis</last_name>
      <phone>440-340-9010</phone>
      <email>jkalapis@crssites.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Gervasi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MidLantic Urology</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittny Goodell</last_name>
      <phone>610-667-0458</phone>
      <email>bgoodell@ucsepa.com</email>
    </contact>
    <contact_backup>
      <last_name>Cheryl M Zinar</last_name>
      <phone>6106670458</phone>
      <email>czinar@ucsepa.com</email>
    </contact_backup>
    <investigator>
      <last_name>Laurence Belkoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra R Montgomery</last_name>
      <phone>843-449-1010</phone>
      <email>amontgomery@curcmb.com</email>
    </contact>
    <investigator>
      <last_name>Neal Shore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Metro Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rezwana M Zahir</last_name>
      <phone>281-912-5762</phone>
      <email>rezwana.zahir@hmutx.com</email>
    </contact>
    <investigator>
      <last_name>Zvi M Schiffman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kethsaly Salinas</last_name>
      <phone>210-617-4116</phone>
      <email>kethsaly.salinas@urologysa.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Saltzstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Jackson</last_name>
      <email>LaurieJackson@Urologyofva.net</email>
    </contact>
    <investigator>
      <last_name>Robert Given</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

